Clinical trials: Cancer of Gastrointestinal Tract
Carcinoma
Data Base Project for Acquisition of Cancer Patient Data in Practices and Ambulant Therapy
The purpose of this registry is to evaluate the situation regarding ambulant therapy of cancer patients in different practices in Germany.
- Trial name
- NCT02303353
- Where
- Germany
- Volunteers
- 2,000 people
- Sponsor
- SPGO Research Mannheim GmbH
Advanced Solid Tumors Cancer
A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors
The primary purpose of this Phase 1, open-label study is to evaluate the safety, pharmacokinetics, and preliminary efficacy of ABBV-368 as a monotherapy and in combination with ABBV-181 in participants with locally advanced or…
- Trial name
- NCT03071757
- Testing
- ABBV-368, ABBV-181
- Where
- 27 sites in United States, France and 4 more
- Volunteers
- 139 people
- Sponsor
- AbbVie
Lung Cancer, Lung Infection
Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath
The goal of this observational study is to develop an advanced expiratory algorithm model utilizing exhaled breath volatile organic compound (VOC) marker molecules.
- Conditions
- Lung Cancer, Lung Infection, COPD, Bronchitis
- Trial name
- NCT06528418
- Testing
- Gas chromatography-mass spectrometry(GC-MS) and micro Gas Chromatography-photoionisation detector (μGC-PID) system
- Where
- China
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- ChromX Health
Solid Tumor, Adult, Colorectal Cancer
Study of IK-595 in RAS- or RAF-altered Advanced Tumors
This is a Phase 1, FIH, Dose Escalation and Dose Expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) effects, and preliminary antitumor activity of IK-595, a MEK/RAF molecular glue…
- Conditions
- Solid Tumor, Adult, Colorectal Cancer, Pancreatic Cancer, Malignant Melanoma
- Trial name
- NCT06270082
- Testing
- IK-595
- Where
- 15 sites in United States
- Volunteers
- 75 people
- Sponsor
- Ikena Oncology
Neoplasms, Breast, Neoplasms, Lung
Study of ESG401 in Adults With Solid Tumors
The primary objective in Phase I is to evaluate the safety and tolerability of ESG401 as a single agent administered in 21-day treatment cycles in previously treated participants with advanced epithelial cancer.
- Conditions
- Neoplasms, Breast, Neoplasms, Lung, Neoplasms,Colorectal, Neoplasms, Bladder
- Trial name
- NCT04892342
- Testing
- ESG401
- Where
- 3 sites in China
- Volunteers
- 156 people
- Sponsor
- Shanghai Escugen Biotechnology Co., Ltd
Melanoma, Non-small Cell Lung Cancer
TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy
TiTAN-1 is a first-in-human study of GEN-011, an experimental treatment being evaluated in adult patients with advanced cancer. GEN-011 is a T cell therapy made specific to each patient, using the patient's own circulating immune…
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma
- Trial name
- NCT04596033
- Testing
- GEN-011, IL-2, Fludarabine
- Where
- 8 sites in United States
- Volunteers
- 49 people
- Sponsor
- Genocea Biosciences, Inc.
Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
- Trial name
- NCT05379985
- Testing
- RMC-6236
- Where
- 21 sites in United States
- Volunteers
- 754 people
- Sponsor
- Revolution Medicines, Inc.
Colon Cancer, Gastrointestinal Cancer
Seal-G / Seal-G MIST Study
A prospective, multi-center, open label, study to evaluate safety and performance of Seal-G and Seal-G MIST in reinforcing colonic anastomosis, in subjects undergoing Colon Resection surgery
- Trial name
- NCT04532515
- Testing
- Seal-G Surgical Sealant, Seal-G MIST System
- Where
- 2 sites in Israel
- Volunteers
- 160 people
- Sponsor
- Advanced Medical Solutions Ltd.
Metastatic Cancer, Solid Tumor
LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors
A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and in Combination with Chemotherapy or Tislelizumab in Patients with Metastatic Solid Tumors
- Conditions
- Metastatic Cancer, Solid Tumor, Pancreatic Cancer, Urothelial Carcinoma
- Trial name
- NCT04666688
- Testing
- LYT-200, Tislelizumab, Gemcitabine/nab-paclitaxel
- Where
- 12 sites in United States
- Volunteers
- 44 people
- Sponsor
- PureTech
Advanced Cancer, Metastatic Melanoma
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
The purpose of this study is to determine the safety of an extracellular signal regulated kinase (ERK1/2) inhibitor LY3214996 administered alone or in combination with other agents in participants with advanced cancer.
- Conditions
- Advanced Cancer, Metastatic Melanoma, Metastatic Non-small Cell Lung Cancer, Colorectal Cancer
- Trial name
- NCT02857270
- Testing
- LY3214996, Midazolam, Abemaciclib
- Where
- 13 sites in United States, Australia and 2 more
- Volunteers
- 210 people
- Sponsor
- Eli Lilly and Company
Solid Tumor, NSCLC
SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET
This is a first-in-human, multicenter, open-label Phase 1/2 study designed to evaluate the safety, efficacy, and tolerability of [225Ac]Ac-FL-261, a targeted radioligand therapy directed at c-MET, in participants with advanced or…
- Conditions
- Solid Tumor, NSCLC, Colorectal Cancer, Head and Neck Cancer
- Trial name
- NCT07873450
- Testing
- [225Ac]Ac-FL-261
- Where
- 2 sites in United States, Australia
- Volunteers
- 208 people
- Sponsor
- Full-Life Technologies UK Limited
Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
This first-in-human (FIH ) study is an open-label, multicenter study that consists of a Phase 1 Dose Escalation/Expansion phase of GB1275 monotherapy or in combination with Anti-PD-1 Antibody or in combination with Standard of…
- Conditions
- Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma
- Trial name
- NCT04060342
- Testing
- GB1275, nab-paclitaxel and gemcitabine, pembrolizumab
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 61 people
- Sponsor
- GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Advanced Solid Tumours, Carcinoma Non-small Cell Lung
First in Human Study of AZD9592 in Solid Tumors
This is a first-in-human (FIH) Phase I, multi-center, open-label, study of AZD9592, in patients with advanced solid tumors. The study consists of several study modules, each evaluating the safety, tolerability, preliminary…
- Conditions
- Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms
- Trial name
- EGRET (NCT05647122)
- Testing
- AZD9592, Osimertinib, 5-Fluorouracil (5-FU)
- Where
- 46 sites in United States, Australia and 9 more
- Volunteers
- 190 people
- Sponsor
- AstraZeneca
Urinary Bladder Neoplasms, Carcinoma, Transitional Cell
A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors
The purpose of the study is to evaluate the safety and to define the Maximal Tolerated Dose (MTD) or the Maximal Administered Dose (MAD) of oral azacitidine as a single agent and in combination with carboplatin (CBDCA) or…
- Conditions
- Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ovarian Neoplasms, Fallopian Tube Neoplasms
- Trial name
- NCT01478685
- Testing
- CC-486, Carboplatin, ABI-007
- Where
- 13 sites in United States, France and 2 more
- Volunteers
- 169 people
- Sponsor
- Celgene
Advanced Solid Tumors, Triple Negative Breast Cancer
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)
The purpose of this study is to determine the safety and efficacy of combination therapy with pembrolizumab (MK-3475) and lenvatinib (E7080/MK-7902) in participants with triple negative breast cancer (TNBC), ovarian cancer…
- Conditions
- Advanced Solid Tumors, Triple Negative Breast Cancer, Ovarian Cancer, Gastric Cancer
- Trial name
- NCT03797326
- Testing
- Pembrolizumab, Lenvatinib
- Where
- 88 sites in United States, Argentina and 15 more
- Volunteers
- 611 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Solid Tumor, Melanoma
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors.
- Conditions
- Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer
- Trial name
- NCT06172478
- Testing
- HER3-DXd
- Where
- 96 sites in United States, Australia and 14 more
- Volunteers
- 740 people
- Sponsor
- Daiichi Sankyo
NSCLC (Advanced Non-small Cell Lung Cancer), Colorectal Cancer
Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors
This is a prospective, open-label, exploratory clinical study to evaluate the safety and preliminary efficacy of allogeneic natural killer (NK) cell injection combined with standard maintenance therapy in patients with locally…
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer), Colorectal Cancer, Advanced Solid Tumors, Advanced Hepatocellular Carcinoma (HCC)
- Trial name
- NCT07551778
- Testing
- NK Cells, NK cells + PD-(L)1 inhibitor + pemetrexed as first-line maintenance therapy, NK cells + cetuximab/bevacizumab + capecitabine as first-line maintenance therapy
- Volunteers
- 42 people
- Sponsor
- BOE Technology Group Co., Ltd.
Cancer, Immunotherapy
Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
This study will collect tumor specimens with correlated clinical and demographic data from patients who are undergoing a biopsy or similar procedure to obtain tumor tissue as a normal course of their medical management or…
- Conditions
- Cancer, Immunotherapy, Advanced Solid Tumors Cancer, Bladder Cancer
- Trial name
- ELEPHAS-05 (NCT07327489)
- Testing
- Biopsy
- Where
- 8 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- Elephas
Lung Cancer, Head and Neck Cancer
First-in-human Study of S-588210 (S-488210+S-488211)
The primary objective is to evaluate the safety and tolerability of S-588210 (S-488210+S-488211) in patients with unresectable recurrent and/or metastatic solid tumors.
- Conditions
- Lung Cancer, Head and Neck Cancer, Bladder Cancer, Esophageal Cancer
- Trial name
- NCT04316689
- Testing
- S-488210, S-488211
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- Shionogi
Colonoscopy
Comparison of 2L NRL994 With NaP Preparation in Colon Cleansing Prior to Colonoscopies for Colon Tumor Screening
To compare the efficacy, acceptability and safety of the new 2 liter gut cleansing solution (Moviprep) and NaP preparation in routine colon cleansing prior to tumor screening colonoscopies
- Trial name
- NCT00427089
- Testing
- Macrogol 3350 Na sulphate NaCl KCl Ascorbic Acid Na Ascorbate, Sodium Phosphate solution (NaP)
- Where
- 12 sites in Germany
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Norgine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.